UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 28, 2011

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Oculus Innovative Sciences, Inc.

File No. 001-33216 – CF# 26337

Oculus Innovative Sciences, Inc. submitted an application under Rule 24b-2

requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on February 4, 2011.

Based on representations by Oculus Innovative Sciences, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.47 through February 8, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel Morris Special Counsel